OSE Immunotherapeutics SA (0RAD.L)
| Previous close | 3.9483 |
| Open | 3.8500 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.8150 - 3.8950 |
| 52-week range | 2.7333 - 7.3100 |
| Volume | |
| Avg. volume | 9,055 |
| Market cap | 518,884 |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®
NANTES, France, November 21, 2023--OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has entered into a collaboration with GenDx (a Eurobio Scientific Company, a key player in the field of specialty in vitro diagnostics) to develop and validate a companion diagnostic (CDx) test to support the confirmatory pivotal Phase 3 clinical trial of Tedopi® cancer vaccine candidate in preparation in Non-Small Cell Lung Cancer (NSCLC) second line treatment. GenDx, o
- Business Wire
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
NANTES, France, October 23, 2023--OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
- Business Wire
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
NANTES, France, October 16, 2023--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).
